Logo image of TMCI

TREACE MEDICAL CONCEPTS INC (TMCI) Stock Fundamental Analysis

NASDAQ:TMCI - Nasdaq - US89455T1097 - Common Stock - Currency: USD

6  -0.21 (-3.38%)

After market: 6 0 (0%)

Fundamental Rating

3

Overall TMCI gets a fundamental rating of 3 out of 10. We evaluated TMCI against 187 industry peers in the Health Care Equipment & Supplies industry. TMCI may be in some trouble as it scores bad on both profitability and health. TMCI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TMCI had negative earnings in the past year.
In the past year TMCI has reported a negative cash flow from operations.
In the past 5 years TMCI always reported negative net income.
TMCI had a negative operating cash flow in each of the past 5 years.
TMCI Yearly Net Income VS EBIT VS OCF VS FCFTMCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

TMCI has a Return On Assets (-25.74%) which is in line with its industry peers.
The Return On Equity of TMCI (-50.30%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -25.74%
ROE -50.3%
ROIC N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
TMCI Yearly ROA, ROE, ROICTMCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

TMCI has a better Gross Margin (80.25%) than 94.12% of its industry peers.
TMCI's Gross Margin has been stable in the last couple of years.
TMCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
TMCI Yearly Profit, Operating, Gross MarginsTMCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TMCI has more shares outstanding
Compared to 5 years ago, TMCI has more shares outstanding
Compared to 1 year ago, TMCI has a worse debt to assets ratio.
TMCI Yearly Shares OutstandingTMCI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TMCI Yearly Total Debt VS Total AssetsTMCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.72, we must say that TMCI is in the distress zone and has some risk of bankruptcy.
TMCI has a Altman-Z score of 1.72. This is comparable to the rest of the industry: TMCI outperforms 56.68% of its industry peers.
TMCI has a Debt/Equity ratio of 0.51. This is a neutral value indicating TMCI is somewhat dependend on debt financing.
TMCI has a Debt to Equity ratio (0.51) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z 1.72
ROIC/WACCN/A
WACC8.86%
TMCI Yearly LT Debt VS Equity VS FCFTMCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

TMCI has a Current Ratio of 4.50. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.50, TMCI is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
A Quick Ratio of 3.36 indicates that TMCI has no problem at all paying its short term obligations.
TMCI has a better Quick ratio (3.36) than 67.91% of its industry peers.
Industry RankSector Rank
Current Ratio 4.5
Quick Ratio 3.36
TMCI Yearly Current Assets VS Current LiabilitesTMCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

TMCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
The Revenue has been growing slightly by 7.54% in the past year.
Measured over the past years, TMCI shows a very strong growth in Revenue. The Revenue has been growing by 39.66% on average per year.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)7.54%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%2.86%

3.2 Future

Based on estimates for the next years, TMCI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.19% on average per year.
TMCI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.54% yearly.
EPS Next Y4.2%
EPS Next 2Y7.89%
EPS Next 3Y6.06%
EPS Next 5Y14.19%
Revenue Next Year9.26%
Revenue Next 2Y9.84%
Revenue Next 3Y8.74%
Revenue Next 5Y14.54%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMCI Yearly Revenue VS EstimatesTMCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
TMCI Yearly EPS VS EstimatesTMCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TMCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TMCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMCI Price Earnings VS Forward Price EarningsTMCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMCI Per share dataTMCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.89%
EPS Next 3Y6.06%

More info and screens

0

5. Dividend

5.1 Amount

TMCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREACE MEDICAL CONCEPTS INC

NASDAQ:TMCI (7/11/2025, 8:00:00 PM)

After market: 6 0 (0%)

6

-0.21 (-3.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners62.71%
Inst Owner Change0%
Ins Owners22.84%
Ins Owner Change8.01%
Market Cap377.40M
Analysts76.67
Price Target10.05 (67.5%)
Short Float %5.94%
Short Ratio6.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.63%
Min EPS beat(2)18.69%
Max EPS beat(2)74.58%
EPS beat(4)4
Avg EPS beat(4)26.25%
Min EPS beat(4)1.96%
Max EPS beat(4)74.58%
EPS beat(8)6
Avg EPS beat(8)13.74%
EPS beat(12)9
Avg EPS beat(12)10.99%
EPS beat(16)12
Avg EPS beat(16)-129.89%
Revenue beat(2)1
Avg Revenue beat(2)-0.36%
Min Revenue beat(2)-1.02%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.57%
Min Revenue beat(4)-1.02%
Max Revenue beat(4)1.65%
Revenue beat(8)6
Avg Revenue beat(8)0.11%
Revenue beat(12)10
Avg Revenue beat(12)2.14%
Revenue beat(16)14
Avg Revenue beat(16)2.79%
PT rev (1m)0%
PT rev (3m)-14.35%
EPS NQ rev (1m)-1.42%
EPS NQ rev (3m)-7.93%
EPS NY rev (1m)2.64%
EPS NY rev (3m)4.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.79
P/FCF N/A
P/OCF N/A
P/B 3.58
P/tB 4.46
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS3.35
BVpS1.67
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.74%
ROE -50.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.25%
FCFM N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
F-Score3
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.95%
Cap/Sales 5.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.5
Quick Ratio 3.36
Altman-Z 1.72
F-Score3
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)349.5%
Cap/Depr(5y)305.94%
Cap/Sales(3y)7.38%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y4.2%
EPS Next 2Y7.89%
EPS Next 3Y6.06%
EPS Next 5Y14.19%
Revenue 1Y (TTM)7.54%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%2.86%
Revenue Next Year9.26%
Revenue Next 2Y9.84%
Revenue Next 3Y8.74%
Revenue Next 5Y14.54%
EBIT growth 1Y7.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.11%
EBIT Next 3Y30.48%
EBIT Next 5Y26.75%
FCF growth 1Y33.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.69%
OCF growth 3YN/A
OCF growth 5YN/A